Clinical evidence for repurposing generics
Many FDA-approved drugs have been studied for cancer uses beyond their original approval. When these drugs go off-patent, the supporting clinical evidence is often left fragmented and difficult to evaluate.
Reboot Rx identifies generic drugs with repurposing potential in cancer, assesses where further study may be warranted, and develops transparent resources to support clinical awareness and informed discussion. Our first resource covers 5-alpha reductase inhibitors in prostate cancer.
Evidence Resource: 5-alpha reductase inhibitors (5-ARIs) in prostate cancer active surveillance
Relevant for: Urologists and clinicians managing prostate cancer with active surveillance
Finasteride and dutasteride have been evaluated in multiple clinical studies examining disease progression and related endpoints in patients with prostate cancer on active surveillance. This resource consolidates the evidence.
What’s inside:
Summaries and key outcomes from 2 randomized controlled trials, 3 meta-analyses, and 10 observational studies
Full references to the underlying literature
Safety considerations
Mechanism of action
Information on drug access
Contribute Clinical Insight
Our first clinician resource focuses on prostate cancer, and we're expanding to other diseases where generic drugs show repurposing potential. If you’re interested in drug repurposing, we value clinical input from all specialties.
Share your perspective
We welcome clinical insight on treatment selection, implementation opportunities, and real-world outcomes.
Collaborate
Participate in pilots, real-world data efforts, and health system partnerships.